Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012. The report details a specific share repurchase transaction executed on September 17, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,600,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,435 pence per share; lowest price paid was 1,418.5 pence per share.
- Treasury Holdings (Settled): 516,315,427 shares (9.43% of total issued share capital).
- Treasury Holdings (Including Unsettled): 521,265,427 shares (10.52% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,956,417,059 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,600,000 shares on September 17, 2012. This transaction increased the proportion of shares held in Treasury from the prior level to 9.43% of issued capital (or 10.52% of voting rights including unsettled shares).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (516,315,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,956,417,059 shares in issue) for disclosure threshold notifications.
- Review the remaining authorization for share buybacks under the mandate granted on May 3, 2012.
- Note that this filing does not contain operational or financial performance data for the period.